Expanded Access Program to Make Niraparib Available to More U.S. Ovarian-cancer Patients

Expanded Access Program to Make Niraparib Available to More U.S. Ovarian-cancer Patients
Women with epithelial-ovarian, fallopian-tube, or primary-peritoneal cancer who are not eligible for niraparib clinical trials, and who lack alternative therapies, may obtain the treatment under the expanded access program (EAP) that TESARO has opened in the United States. Under the program, those whose cancer recurred after a complete or partial response to platinum-based chemotherapy will

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *